FDA Warning Letters on Exosome Products | Regulatory & Criminal Defense
FDA Warning Letters on Exosome Products: Regulatory Classification, Enforcement Trends, and Criminal Risks
The FDA is issuing warning letters to exosome product companies at an accelerating pace. In the span from late 2024 through early 2026, the agency sent enforcement letters to Evolutionary Biologics, Chara Biologics, Supreme Rejuvenation, New Life Medical Services, Innate Healthcare Institute, and Dynamic Stem Cell Therapy. Each letter carries the same core finding: these products are unapproved new drugs and unlicensed biological products under federal law.
The warning letters are not isolated regulatory events. They sit within a broader enforcement pattern that now includes DOJ criminal prosecutions, FTC deceptive advertising actions, FDA permanent debarment orders, and federal court injunctions against clinics and manufacturers. In March 2026, the FDA updated its consumer warning on unapproved products from human cells or tissues, stating that entities that violate the FD&C Act or the PHS Act may be the subject of legal action without further notice, including seizure and injunction.
For manufacturers, distributors, clinic operators, and physicians involved in sourcing or administering exosome products, these enforcement actions create overlapping regulatory, civil, and criminal exposure.
What Are Exosomes?
Exosomes are extracellular vesicles. They are small, membrane-bound particles, typically between 30 and 150 nanometers in diameter, that cells release as part of normal biological communication. Cells produce exosomes by budding inward within compartments called multivesicular bodies, then releasing the vesicles into the extracellular space. The vesicles carry proteins, lipids, and RNA from the originating cell to recipient cells.
The scientific interest in exosomes is legitimate. Preclinical research has explored their potential roles in tissue repair, immune modulation, and cell-to-cell signaling. Multiple exosome-based therapeutics have entered Phase I and Phase II clinical trials under FDA-authorized Investigational New Drug applications. These trials cover applications in cardiovascular disease, graft-versus-host disease, and neurodegenerative conditions.
But research interest is not the same as regulatory approval. No exosome product has completed the FDA’s drug approval process. Not one. The FDA’s Public Safety Notification on Exosome Products states this directly. The commercial market for exosome products has grown dramatically, with products derived from umbilical cord tissue, amniotic fluid, placental tissue, and Wharton’s jelly marketed for orthopedic, neurological, dermatological, and anti-aging applications. The regulatory framework has not kept pace with the commercial demand, creating enforcement risk across the supply chain.
The FDA’s consumer information page on regenerative medicine therapies states: unapproved products include stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton’s jelly, ortho-biologics, and exosomes. The FDA has received reports of blindness, tumor formation, infections, and more due to the use of these unapproved products.
How the FDA Classifies Exosome Products
The regulatory classification determines everything that follows. Products intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or function of the body, are drugs as defined in Section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1). Exosome products that meet this definition are also biological products as defined in Section 351(i) of the Public Health Service Act, 42 U.S.C. § 262(i). A biological product may not be introduced into interstate commerce unless a biologics license is in effect for it under Section 351(a) of the PHS Act. A new drug may not be introduced into interstate commerce without an approved application under Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a). A biological product with an approved BLA is not required to also have an approved NDA. 42 U.S.C. § 262(j).
The Minimal Manipulation Barrier
Some manufacturers have argued that their exosome products qualify as HCT/Ps (human cells, tissues, and cellular and tissue-based products) regulated solely under Section 361 of the PHS Act and 21 C.F.R. § 1271.10(a). To qualify for that pathway, a product must meet all four criteria in Section 1271.10(a): it must be minimally manipulated; it must be intended for homologous use only; its manufacture must not involve combination with another article (with limited exceptions); and it must either have no systemic effect and not be dependent on metabolic activity of living cells, or be for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use. The FDA has found in every warning letter to exosome companies that the products fail to meet at least one of these criteria. The FDA’s consistent position is that exosome isolation from cultured or expanded cells constitutes more than minimal manipulation of the source tissue, and that the therapeutic claims in the company’s marketing materials establish that the products are not intended for homologous use. Either failure independently disqualifies the product from regulation solely under Section 361 and subjects it to premarket review as a drug and biological product under Section 351 of the PHS Act and Section 505 of the FD&C Act.
Registration Is Not Approval
A recurring misrepresentation in the exosome market involves companies equating FDA facility registration with FDA product approval. Facility registration under 21 C.F.R. Part 1271 is an administrative filing requirement. It does not mean the FDA has reviewed, tested, cleared, or approved any product manufactured at that facility. The FDA has cited this distinction repeatedly in its warning letters. Language such as “FDA registered,” “FDA compliant,” or “cGMP certified” in marketing materials does not establish lawful authority to distribute a product for therapeutic use.
Products (as of 2026)
Late 2024 Through 2026
of Unapproved Biologics Firm
Recent FDA Warning Letters: Late 2024 Through 2026
The FDA’s recent warning letters demonstrate an intensifying enforcement posture. Each letter follows the same analytical framework: the FDA identifies the products, catalogs the therapeutic claims, determines that the products are drugs and biological products under federal law, and warns that failure to comply may result in seizure, injunction, or criminal referral.
Dynamic Stem Cell Therapy (February 2026)
In February 2026, the FDA issued a warning letter to Dynamic Stem Cell Therapy after reviewing the company’s website. The letter identified an umbilical cord-derived stem cell product marketed for allogeneic use and found it to be misbranded. The letter also noted that the company marketed exosome products, and the FDA directed the company to its Public Safety Notification on Exosome Products. The product lacked an approved BLA. The FDA stated that a biologics license is issued only after demonstrating that a product is safe, pure, and potent.
New Life Medical Services (September 2025)
The FDA issued a warning letter to New Life Medical Services after an on-site inspection documented the company selling umbilical cord products, an amniotic fluid product, and an exosome product called “Rexo” for allogeneic use. The FDA reviewed the company’s website and Instagram page, both of which contained treatment claims for neuropathy, bone spurs, pain, and inflammation. The FDA also identified additional products, “Restor Charge” and “Rexo Charge,” marketed on Instagram with claims about healing potential. The FDA demanded a customer list for each product.
Innate Healthcare Institute (August 2025)
The FDA issued a warning letter to Innate Healthcare Institute after reviewing the company’s website. The letter found that the company marketed umbilical cord mesenchymal stem cells with claims about treating autoimmune conditions, autism, COPD, heart disease, and other conditions. The website referenced exosomes as part of the stem cell mechanism of action. The FDA directed the company to the exosome Public Safety Notification and classified the product as misbranded.
Supreme Rejuvenation (May 2025)
The FDA’s warning letter to Supreme Rejuvenation cited marketing of “100 Billion Exosomes: Human Umbilical Cord Mesenchymal Stem Cell Derived Exosomes” and exosome gel products. The company’s website and Instagram page made treatment claims for fibromyalgia, diabetes, psoriasis, eczema, rosacea, acne, women’s health conditions, and neurological conditions. The company’s website also included a “research purposes only” disclaimer. The FDA noted that no IND was in effect for the products and that the disclaimer did not change the regulatory analysis.
“Although your website includes statements that your products are for ‘research and investigational purposes and are not approved for general medical use,’ there is no IND in effect for your product. Nor is there a valid biologics license.”
— FDA Warning Letter to Supreme Rejuvenation, LLC (May 5, 2025)Chara Biologics (January 2025)
The FDA’s warning letter to Chara Biologics is significant for an additional violation. Beyond classifying CharaExo as an unapproved new drug and unlicensed biologic, the FDA found that the company extended the manufacturer’s expiration date by one year or more without supporting data. This is a misbranding violation under Section 502(a) of the FD&C Act, 21 U.S.C. § 352(a). The letter also noted that the FDA had previously notified Chara Biologics in November 2019 about its products. The company’s responses over five years were found inadequate. Its brochure listed therapeutic claims for autoimmune disorders, neurodegenerative conditions, diabetes, cardiovascular disease, autism, spinal cord injuries, and cirrhosis.
Evolutionary Biologics (December 2024)
The FDA’s warning letter to Evolutionary Biologics cited an extensive product line: EXO RNA™, EVO JEL™, EVO HYBRID™, EXO RX™, EXO ELIXIR™, and EXO PERIO™. The therapeutic claims ranged from neurodegenerative disease treatment and tissue regeneration to wound healing and periodontal applications. The website stated that MSC exosomes could penetrate the blood-brain barrier and stimulate neuronal growth. The FDA warned that continued distribution could result in seizure or injunction without further notice.
The Enforcement Escalation: From Warning Letters to Federal Prison
Warning letters are administrative actions. They are the opening move. The enforcement toolkit extends further.
Criminal Prosecution: United States v. Kosolcharoen
The prosecution of John Kosolcharoen demonstrates the end of the enforcement spectrum. Kosolcharoen founded two companies to manufacture and distribute injectable stem cell products made from human umbilical cord blood. The products were marketed under the brand name “ReGen” for conditions including lung disease, heart disease, autoimmune disorders, Alzheimer’s disease, and Parkinson’s disease.
Kosolcharoen was sentenced to 36 months in federal prison in September 2024 after pleading guilty to one count of introducing an unapproved new drug into interstate commerce with the intent to defraud and mislead. The government alleged that sales of Liveyon products generated approximately $21.6 million in revenue. The CDC documented that the products were linked to hospitalizations of 19 patients in eight states for bacterial infections. Kosolcharoen admitted he directed purchase orders to falsely state that products were sold “for research purposes only” and that he misled the public about adverse events.
In March 2025, the FDA issued a permanent debarment order against Kosolcharoen, barring him from providing services to any person with an approved or pending drug product application, including biologics license applications.
Civil Injunction: United States v. U.S. Stem Cell Clinic
DOJ obtained a permanent injunction against U.S. Stem Cell Clinic after the company continued marketing unapproved products following a 2017 warning letter. The Eleventh Circuit affirmed that the clinic’s products were adulterated and misbranded drugs subject to FDA regulatory authority. The Ninth Circuit reached the same conclusion in United States v. California Stem Cell Treatment Center, affirming FDA authority over these products in 2024.
FTC Enforcement: Permanent Bans and Monetary Penalties
The Federal Trade Commission has pursued parallel enforcement. In January 2025, the FTC obtained permanent bans against the co-founders of a stem cell institute and ordered more than $5.1 million in refunds and penalties for deceptive marketing. FTC enforcement under Section 5 of the FTC Act does not require proof of criminal intent. It requires only that the advertising is deceptive or unfair.
Misbranding: A Distinct and Compounding Risk
Misbranding is an independent violation that many companies overlook. A product is misbranded under 21 U.S.C. § 352 if its labeling is false or misleading in any particular. The term “labeling” under the FD&C Act is broader than the physical label. It includes websites, social media accounts, brochures, training videos, Instagram posts, and YouTube lectures. The FDA has cited all of these as labeling in recent warning letters.
The Chara Biologics letter illustrates the point. The company extended expiration dates without supporting data. That is a false statement on the product’s labeling. It is an independent misbranding violation that can support product seizure even apart from the unapproved drug classification.
Criminal Statutes That Apply to Exosome Product Violations
The criminal exposure is not theoretical. DOJ has charged and convicted individuals under these statutes in the regenerative medicine context.
The Chain of Liability: Who Is Exposed
Enforcement does not stop at the manufacturer. Every participant in the distribution chain faces potential liability. The FDA’s warning letters have demanded customer lists from manufacturers, a step that expands the investigation downstream to distributors, clinics, and administering physicians.
| Role | Regulatory and Criminal Exposure | How Enforcement Reaches Them |
|---|---|---|
| Manufacturer | FDA warning letters, Form 483 observations, product seizure, injunction, criminal prosecution, permanent debarment | FDA facility inspections, website surveillance, adverse event reports, DOJ referral |
| Distributor | Introduction of unapproved drug into interstate commerce, conspiracy | FDA review of manufacturer customer lists, shipping records, distribution agreements |
| Clinic / Med Spa Operator | Administering unapproved drug, misbranding, state medical board discipline, malpractice liability | FDA website and social media surveillance, patient complaints, adverse event reports, FTC advertising review |
| Administering Physician | State board action, federal criminal liability, malpractice exposure, loss of DEA registration | Adverse events, patient complaints, qui tam whistleblowers, state board referrals |
| Sales Representatives / Marketers | Wire fraud, conspiracy, FTC deceptive practices enforcement | Marketing materials, recorded presentations, social media content, email and text communications |
DOJ’s Health & Safety Unit: A New Enforcement Vector
In December 2025, DOJ established the Health & Safety Unit within the Criminal Division’s Fraud Section. The HSU was created to centralize criminal enforcement of the FD&C Act, including cases involving adulterated, misbranded, or counterfeit drugs, medical devices, and dietary supplements. The unit absorbed prosecutors from the disbanded Consumer Protection Branch and is staffed to handle complex, multi-district FDCA matters.
The HSU’s stated mandate covers misconduct involving product quality and safety, integrity of safety data and certifications, and failures in systems or disclosures that conceal safety risks. Distribution of unapproved exosome and stem cell products with false claims about safety and effectiveness falls directly within this mandate. The Kosolcharoen prosecution, which was brought by the Consumer Protection Branch before its dissolution, is the type of case that now falls to the HSU. Companies and individuals in the regenerative medicine space face a dedicated federal prosecution unit with nationwide jurisdiction and the full range of Fraud Section enforcement tools.
Defense Considerations
Regulatory Classification Analysis
The threshold defense question is whether a specific product is properly classified as a drug or biological product. The FDA’s position on exosome products is well-established. But the HCT/P regulatory framework under 21 C.F.R. Part 1271 involves factual determinations about minimal manipulation, homologous use, and manufacturing processes. Defense counsel analyzes each product against the criteria in 21 C.F.R. § 1271.10(a) and the FDA’s applicable guidance documents.
The Intent Element: Felony Versus Misdemeanor
The distinction between a misdemeanor and a felony under the FD&C Act turns on intent. A first offense without intent to defraud or mislead is a misdemeanor. With intent to defraud or mislead, the same conduct is a felony carrying up to ten years. Evidence of reliance on regulatory counsel, good-faith compliance efforts, voluntary cessation of distribution, and cooperative engagement with the FDA are all relevant to the intent analysis. Conversely, continued distribution after a warning letter, use of “research only” disclaimers that contradict actual sales practices, and concealment of adverse events are powerful evidence of intent.
The Warning Letter Response
An FDA warning letter demands a written response within 15 business days. The response creates a record. It is not privileged. Statements made in the response can be used in a subsequent criminal proceeding. This creates the same strategic dilemma that arises in other healthcare enforcement contexts. The regulatory process demands speed. A parallel or potential criminal investigation demands caution. Responding without counsel who understands both the regulatory and criminal dimensions is a significant risk.
Frequently Asked Questions
Are exosome products FDA-approved for any therapeutic use?
No. As of 2026, no exosome product has been approved by the FDA for any therapeutic use in humans. The FDA has stated this in its Public Safety Notification on Exosome Products and in every warning letter issued to exosome manufacturers and distributors. Exosome products intended for therapeutic use are classified as drugs under 21 U.S.C. § 321(g)(1) and biological products under Section 351 of the PHS Act. The only lawful pathway for administering exosome products for therapeutic purposes is under an FDA-authorized Investigational New Drug application within a structured clinical trial.
What is the difference between FDA facility registration and FDA product approval for exosome manufacturers?
FDA facility registration under 21 C.F.R. Part 1271 is an administrative filing for establishments that manufacture HCT/Ps. It does not constitute FDA review, evaluation, clearance, or approval of any product made at that facility. FDA product approval requires submission and approval of a Biologics License Application, which involves clinical trial data demonstrating safety, purity, and potency. The FDA has cited the conflation of registration with approval as a misleading practice in multiple warning letters to exosome companies. Marketing an exosome product as “FDA registered” to imply FDA endorsement creates misbranding exposure under 21 U.S.C. § 352.
What are the federal criminal penalties for distributing unapproved exosome products?
Distributing unapproved exosome products in interstate commerce violates 21 U.S.C. § 331(d). A first offense without intent to defraud is a misdemeanor carrying up to one year of imprisonment. With intent to defraud or mislead, it is a felony carrying up to ten years under 21 U.S.C. § 333(a)(2). Federal prosecutors may also bring wire fraud charges under 18 U.S.C. § 1343, which carries up to 20 years per count, and conspiracy charges under 18 U.S.C. § 371. In September 2024, the CEO of a company that distributed unapproved injectable stem cell products was sentenced to 36 months in federal prison.
What is a misbranded drug under the Federal Food, Drug, and Cosmetic Act?
A drug is misbranded under 21 U.S.C. § 352 if its labeling is false or misleading in any particular, or if it lacks adequate directions for use. The term “labeling” under the FD&C Act extends beyond the physical product label. It includes websites, brochures, social media posts, Instagram pages, YouTube lectures, training videos, and promotional materials associated with the product. In the exosome context, the FDA has found products misbranded when companies extended expiration dates without supporting data, made disease treatment claims without an approved BLA, or used language implying FDA endorsement. Misbranding is an independent violation that can support product seizure, injunction, and criminal charges.
Does a “for research purposes only” disclaimer protect exosome manufacturers from FDA enforcement?
No. The FDA has directly addressed this disclaimer in warning letters. In the May 2025 warning letter to Supreme Rejuvenation, the FDA noted that although the company’s website stated its products were for “research and investigational purposes,” no IND was in effect and no valid biologics license existed. When marketing materials, dosing protocols, sales practices, and customer communications demonstrate that products are sold for clinical use in patients, a research-only disclaimer does not change the regulatory classification. The Kosolcharoen debarment order noted that the defendant directed purchase orders to falsely state products were sold “for research purposes only” to mislead the FDA about the company’s actual activities.
What happens after a company receives an FDA warning letter for exosome products?
An FDA warning letter requires a written response within 15 business days outlining specific corrective actions taken or planned. If the company does not adequately address the violations, the FDA may pursue enforcement without further notice. Available remedies include product seizure under 21 U.S.C. § 334, injunction under 21 U.S.C. § 332, and criminal referral to DOJ. The response to a warning letter is not privileged. Statements and documents submitted become part of the administrative record, which federal law enforcement can access. In the Chara Biologics matter, the FDA documented that the company’s responses over a five-year period were inadequate and that violations persisted.
Can a physician face federal criminal liability for administering exosome products to patients?
A physician who administers an exosome product that is an unapproved drug or unlicensed biologic faces exposure at multiple levels. Federal enforcement under the FD&C Act can reach physicians who administer unapproved drugs with knowledge that the products lack FDA approval. The Ninth Circuit in United States v. California Stem Cell Treatment Center and the Eleventh Circuit in United States v. U.S. Stem Cell Clinic both affirmed FDA authority over these products. State medical boards can initiate disciplinary proceedings, potentially resulting in license suspension or revocation. Malpractice liability increases substantially when a physician administers a product that has not been evaluated through the FDA’s approval process. Adverse event reports from patients have triggered investigations that escalated to criminal referrals.
What adverse events has the FDA documented from unapproved exosome and stem cell products?
The FDA’s regenerative medicine consumer information page reports blindness, tumor formation, and infections from unapproved products including exosomes, stem cells, and Wharton’s jelly. The FDA’s Public Safety Notification on Exosome Products was issued after the CDC reported serious adverse events in patients treated in Nebraska. In the Kosolcharoen prosecution, the CDC documented that the defendant’s stem cell products were linked to hospitalizations of 19 patients in eight states for bacterial infections. Contamination risks remain significant because many exosome products are manufactured without validated sterility procedures.
Does an FDA IND for one indication authorize commercial distribution of exosome products for other uses?
No. An Investigational New Drug application authorizes the use of a specific product for a specific indication within a structured clinical trial under specific conditions. It does not authorize commercial distribution for other indications or general clinical use. The FDA addressed this directly in the Kimera Labs matter. After the company obtained an IND for a COVID-19 inflammation study, the FDA nonetheless issued a warning letter finding that the company’s continued commercial distribution of exosome products for other uses violated the FD&C Act and PHS Act. An IND is a pathway for investigation. It is not a license for commercial sale.
What role does the FTC play in enforcement against exosome and regenerative medicine products?
The Federal Trade Commission enforces Section 5 of the FTC Act, which prohibits deceptive or unfair acts or practices in commerce. The FTC has pursued enforcement actions against clinics making unsubstantiated health claims about regenerative medicine products, including stem cell and exosome therapies. In January 2025, the FTC obtained permanent bans and ordered more than $5.1 million in refunds and penalties against the co-founders of a stem cell institute. FTC enforcement does not require proof of criminal intent. The FTC can impose civil penalties, require consumer refunds, and obtain permanent industry bans. FTC enforcement operates in parallel with FDA and DOJ actions.
What experience does Armstrong & Bradylyons PLLC bring to FDA enforcement and regenerative medicine fraud defense?
Scott Armstrong is a former Assistant Chief at DOJ’s Fraud Section who tried sixteen complex federal cases in federal courts around the country, including nine healthcare fraud jury trials. He served as lead counsel in healthcare fraud cases totaling over $600 million in false claims to federal healthcare programs. Drew Bradylyons is a former Assistant Chief at DOJ’s Fraud Section who supervised the Healthcare Fraud Unit’s South Florida Strike Force and investigated cases involving more than $1 billion in fraudulent claims. Together, the firm’s attorneys have over 25 years of combined DOJ experience and participated in 25 federal jury trials, including 17 in healthcare fraud cases. The firm’s stem cell and regenerative medicine fraud defense practice covers FDA warning letter responses, DOJ criminal investigations, FTC enforcement actions, and parallel civil and administrative proceedings involving unapproved biological products.
